SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 4, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed12d 7h ago
Insider cluster: 2 insiders, $311K total
Actionable Insight • Neutral

The insider sales are too small to signal a change in fundamentals. Monitor next 10-Q for any guidance revision or royalty revenue trends.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$299.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
+5.78%
T+5 · $316.27 · next T+20 in 17d
Vs SPY
+2.49%
α at T+5
Latest observation
+1.82%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $299.00entry
  2. T+1 · 11d ago +2.41%α +2.10% · $306.20
  3. T+5 · 5d ago +5.78%α +2.49% · $316.27
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Ligand Pharmaceuticals sold a total of $311K in open-market sales within a week of the company's Q3 2026 earnings release. The CLO sold under a 10b5-1 plan, while a director sold without one. The total value is 0.005% of the $6.1B market cap, making the cluster trivial in scale.

Key Financial Metrics

Direction
selling
Total Value
$311.0K
Insiders
2

Key Facts

  • Total open-market sales: $311K (0.005% of $6.1B market cap)
  • CLO Andrew Reardon sold $87K under a 10b5-1 plan
  • Director Jason Aryeh sold $224K without a 10b5-1 plan
  • Sales occurred within 6 days of Q3 2026 earnings (royalty revenue +51% YoY, raised EPS guidance)
  • No C-suite CEO or CFO trades in the cluster

Financial Impact

Total insider sales of $311K, negligible relative to $6.1B market cap

Risk Factors

  • Insider sales are trivial in size and do not indicate material bearish conviction
  • CLO's sale under a 10b5-1 plan suggests pre-planned liquidity, not a reaction to earnings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1793827435938

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Viewing Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 9h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026